Press Releases
October 2023
10.26.2023 Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Against Influenza and COVID-19 10.20.2023 Prescription Medicines Vaccines FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents 10.15.2023 Corporate Partnerships Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023 10.13.2023 Corporate Finance Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance 10.13.2023 Prescription Medicines Medicines U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC) 10.12.2023 Prescription Medicines Medicines U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer 10.05.2023 Pfizer Presents New Data at IDWeek 2023 Highlighting Advances in Prevention and Treatment of Certain Respiratory Illnesses and Other Infectious Diseases 10.04.2023 Financial Finance Pfizer Declares Fourth-Quarter 2023 Dividend
September 2023
09.22.2023 Vaccines Vaccines Pfizer Broadens Portfolio of Respiratory Vaccines Recommended by CDC Advisory Committee with ABRYSVO™ for RSV 09.19.2023 Financial Finance Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference 09.19.2023 Prescription Medicines European Commission Approves Pfizer’s LITFULO™ for Adolescents and Adults With Severe Alopecia Areata 09.18.2023 Financial Finance Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts
Resource Library
Press Kits
These downloadable files, including fact sheets about Pfizer and approved images or videos, are packages curated by the Global Media Relations team for use by professional journalists.
Contact Pfizer Media Relations
Media Contacts
United States, Canada, and Latin America
+1 212.733.1226
Europe, Middle East, and Africa
+44-(0)845.300.8033
Asia Pacific
+65.918.732.47
Email
[email protected]
Though intended for professional media, these resources may also be interesting to patients, healthcare professionals, and investors. The media relations team is focused on responding to media inquiries. However, we want to ensure that customers, investors, and others receive the appropriate attention.
For patients or healthcare professionals with questions about Pfizer’s vaccines or medicines, please see our global list of medical information contacts.
For investors with questions about Pfizer’s efforts, please visit our contact page and select "Shareholder Services".
For all other non-media inquiries, please visit the contact us page to reach the appropriate Pfizer contact.